Mississippichronicle

(Albany, United States) As per DelveInsight’s assessment, globally, the Chemotherapy Induced Nausea and Vomiting Pipeline constitutes 15+ key companies continuously working towards developing 15+ Chemotherapy Induced Nausea and Vomiting Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

In the Chemotherapy Induced Nausea and Vomiting pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Chemotherapy Induced Nausea and Vomiting NDA approvals (if any), and product development activities comprising the technology, Chemotherapy Induced Nausea and Vomiting collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

To explore more information on the latest breakthroughs in the Chemotherapy Induced Nausea and Vomiting Pipeline treatment landscape of the report, click here @ Chemotherapy Induced Nausea and Vomiting Pipeline Outlook

Key Takeaways from the Chemotherapy Induced Nausea and Vomiting Pipeline Report

• DelveInsight’s Chemotherapy Induced Nausea and Vomiting Pipeline analysis depicts a robust space with 15+ active players working to develop 14+ pipeline treatment therapies.
• The leading companies working in the Chemotherapy Induced Nausea and Vomiting Market include Acacia Pharma, Camurus, LP Pharmaceuticals, Skye Bioscience, TALLC Corporation, Starton Therapeutics, and others.
• Promising Chemotherapy Induced Nausea and Vomiting Pipeline Therapies in the various stages of development include SP-01 (Granisetron Transdermal Delivery System), Granisetron Hydrochloride Tablet, Pro-netupitant/Palonosetron, Netupitant/Palonosetron, Dexamethasone, Aprepitant, I.V. palonosetron, and others.
• On January 2023, Xiamen LP Pharmaceutical Co., Ltd announced a study of phase 3 clinical trials for Palonosetron HCl Buccal Film 0.5 mg. The phase 3 study is to compare the efficacy and safety of palonosetron, a long-acting 5-HT3 receptor antagonist, by buccal film delivery compared to IV injection for the prevention of chemotherapy-induced nausea and vomiting. Subjects receive a single dose of palonosetron prior to moderately emetogenic chemotherapy.
• On April 2023, Solasia Pharma K.K. announced a study of phase 3 clinical trials for Granisetron Hydrochloride Tablet and SP-01 (Granisetron Transdermal Delivery System). The purpose of this study is to assess the efficacy and safety of SP-01 in chemotherapy-induced nausea and vomiting (CINV) associated with the administration of moderately or highly emetogenic (ME or HE) multi-day chemotherapy which will provide scientific and reliable clinical data in the drug registration in China.

Chemotherapy Induced Nausea and Vomiting Overview

Chemotherapy Induced Nausea and Vomiting (CINV) are the side effects of cancer chemotherapy that can cause significant negative impacts on patients’ quality of life and on their ability to tolerate and comply with therapy.

For further information, refer to the detailed Chemotherapy Induced Nausea and Vomiting Unmet Needs, click here for Chemotherapy Induced Nausea and Vomiting Ongoing Clinical Trial Analysis

Chemotherapy Induced Nausea and Vomiting Emerging Drugs Profile

• APD403: Acacia Pharma

APD403 is based on the selective dopamine antagonist amisulpride. It is being developed as an intravenous injection for cancer patients to be administered immediately before they receive chemotherapy to prevent acute CINV, and as an oral tablet to prevent delayed CINV. The drug is currently in Phase II clinical studies for Chemotherapy-induced nausea and vomiting.

• CAM2047: Camurus

CAM2047 is along-acting subcutaneous granisetron depot for in development for the treatment of acute and delayed chemotherapy-induced nausea and vomiting. It is currently under Phase I stage of development for the treatment of Chemotherapy-induced nausea and vomiting.

Chemotherapy Induced Nausea and Vomiting Pipeline Therapeutics Assessment

There are approx. 15+ key companies which are developing the therapies for Chemotherapy Induced Nausea and Vomiting. The companies which have their Chemotherapy Induced Nausea and Vomiting drug candidates in the most advanced stage, i.e. phase II include, Acacia Pharma.

Request a sample and discover the recent advances in Chemotherapy Induced Nausea and Vomiting Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Chemotherapy Induced Nausea and Vomiting Segmentation

Chemotherapy Induced Nausea and Vomiting Drugs and Companies

• SP-01 (Granisetron Transdermal Delivery System): Solasia Pharma K.K.
• Granisetron Hydrochloride Tablet: Proswell Medical Corporation
• Palonosetron: Helsinn Healthcare SA

Chemotherapy Induced Nausea and Vomiting Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Some of the Companies in the Chemotherapy Induced Nausea and Vomiting Therapeutics Market include-

Acacia Pharma, Camurus, LP Pharmaceuticals, Skye Bioscience, TALLC Corporation, Starton Therapeutics, and others.

Dive deep into rich insights for drugs for Chemotherapy Induced Nausea and Vomiting Pipeline, click here @ Chemotherapy Induced Nausea and Vomiting Unmet Needs and Analyst Views

Scope of the Chemotherapy Induced Nausea and Vomiting Pipeline Report

• Coverage- Global
• Companies- Acacia Pharma, Camurus, LP Pharmaceuticals, Skye Bioscience, TALLC Corporation, Starton Therapeutics, and others.
• Therapies- SP-01 (Granisetron Transdermal Delivery System), Granisetron Hydrochloride Tablet, Pro-netupitant/Palonosetron, Netupitant/Palonosetron, Dexamethasone, Aprepitant, I.V. palonosetron, and others.
• Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Chemotherapy Induced Nausea and Vomiting Merger and acquisitions, Licensing Activities

Table of Content

1. Introduction
2. Executive Summary
3. Chemotherapy Induced Nausea and Vomiting: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chemotherapy Induced Nausea and Vomiting – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Chemotherapy Induced Nausea and Vomiting Collaboration Deals
9. Late Stage Products (Phase III)
10. Drug name: Company name
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. APD403: Acacia Pharma
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. CAM2047: Camurus
17. Drug profiles in the detailed report…..
18. Preclinical and Discovery Stage Products
19. TA-A002: TALLC Corporation
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Chemotherapy Induced Nausea and Vomiting Key Companies
23. Chemotherapy Induced Nausea and Vomiting Key Products
24. Chemotherapy Induced Nausea and Vomiting- Unmet Needs
25. Chemotherapy Induced Nausea and Vomiting- Market Drivers and Barriers
26. Chemotherapy Induced Nausea and Vomiting- Future Perspectives and Conclusion
27. Chemotherapy Induced Nausea and Vomiting Analyst Views
28. Chemotherapy Induced Nausea and Vomiting Key Companies
29. Appendix

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services